← back to search

Haiying Zhang

Jilin University · CN
Area of research
Cancer Research · Molecular Biology
Research interest
Research interests include Extracellular vesicles in disease, Inflammatory Bowel Disease, MicroRNA in disease regulation, and Cancer-related molecular mechanisms research.
h-index
42
citations
23,524
works
227
NIH funding
primary concept
Medicine
email

Recent publications

Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer
Nature Medicine 2024cited by 52position: middledoi
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression
Nature Cancer 2024cited by 25position: middledoi
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression.
2024cited by 16position: contributordoi
Total flavonoids of Astragalus protects glomerular filtration barrier in diabetic kidney disease
Chinese Medicine 2024cited by 14position: middledoi
ZEB1-AS1 as a TRPML1 Inhibitor to Cause Lysosome Dysfunction and Cardiac Damage in Aged Mice
Engineering 2024cited by 4position: middledoi
Optimization of ultracentrifugation-based method to enhance the purity and proteomic profiling depth of plasma-derived extracellular vesicles and particles.
2024cited by 2position: contributordoi
Tumour-derived Extracellular Vesicle and Particle Reprogramming of Interstitial Macrophages in the Lung Pre-Metastatic Niche Enhances Vascular Permeability and Metastatic Potential
2024cited by 2position: contributordoi
Tumour extracellular vesicles and particles induce liver metabolic dysfunction
Nature 2023cited by 254position: middledoi
Tumour extracellular vesicles and particles induce liver metabolic dysfunction.
2023cited by 205position: contributordoi
Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas
Theranostics 2023cited by 15position: middledoi
Data from <i>KRAS</i><sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
2023cited by 0position: contributordoi
Supplementary Tables from <i>KRAS</i><sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
2023cited by 0position: contributordoi
Supplementary Tables from <i>KRAS</i><sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
2023cited by 0position: contributordoi
Supplementary Figures from <i>KRAS</i><sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
2023cited by 0position: contributordoi
Data from <i>KRAS</i><sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
2023cited by 0position: contributordoi
Supplementary Figures from <i>KRAS</i><sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
2023cited by 0position: contributordoi
Extracellular vesicles and particles impact the systemic landscape of cancer
The EMBO Journal 2022cited by 120position: middledoi
Extracellular vesicles and particles impact the systemic landscape of cancer.
2022cited by 103position: contributordoi
M<sub>3</sub> Muscarinic Acetylcholine Receptor Antagonist Darifenacin Protects against Pulmonary Fibrosis through ERK/NF-κB/miR-21 Pathway
American Journal of Molecular Biology 2022cited by 1position: middledoi
An exosome pathway without an ESCRT.
2021cited by 69position: contributordoi
MiR-34a suppression targets Nampt to ameliorate bone marrow mesenchymal stem cell senescence by regulating NAD+-Sirt1 pathway
Stem Cell Research & Therapy 2021cited by 44position: middledoi
<i>KRAS</i> <sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
2021cited by 33position: contributordoi
Tumour-regulated anorexia preceding cachexia.
2021cited by 7position: contributordoi
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Cell 2020cited by 1,228position: middledoi
An exosome pathway without an ESCRT
Cell Research 2020cited by 85position: middledoi
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
Journal of Crohn s and Colitis 2020cited by 66position: middledoi
Extracellular vesicle and particle isolation from human and murine cell lines, tissues, and bodily fluids
STAR Protocols 2020cited by 40position: middledoi
Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization
Nature Protocols 2019cited by 461position: firstdoi
Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis
Nature Cell Biology 2019cited by 429position: middledoi
Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization.
2019cited by 347position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 16 papers (2019–2024)David Lyden · Memorial Sloan Kettering Cancer Center14 papers (2019–2024)Charles M. Rudin · Memorial Sloan Kettering Cancer Center8 papers (2019–2023)Kathryn C. Arbour · University College London7 papers (2021–2023)Bob T. Li · Presbyterian Hospital7 papers (2021–2023)Alexander Drilon · Université Grenoble Alpes7 papers (2021–2023)Yonina R. Murciano-Goroff · CancerCare7 papers (2021–2023)Neal Rosen · Memorial Hospital7 papers (2021–2023) · 7 papers (2021–2023)Daniela Molena · Oregon Health & Science University7 papers (2021–2023)David Lyden · Cornell University7 papers (2014–2022)Chinyu Su · Shenyang Pharmaceutical University6 papers (2015–2020)Julián Panés · Instituto de Salud Carlos III5 papers (2015–2020) · 4 papers (2017–2020)William J. Sandborn · Mirati Therapeutics (United States)4 papers (2015–2020)Han Sang Kim · Sungkyunkwan University3 papers (2019–2023)Irina Matei · Cornell University3 papers (2014–2020)Bruce E. Sands · Seattle University3 papers (2017–2019)Séverine Vermeire · Europe Hospitals3 papers (2017–2020)Candia M. Kenific · Cornell University3 papers (2020–2022)